Autoimmune disorders are conditions in which the immune system mistakenly attacks the body’s own healthy cells and tissues, causing chronic inflammation and organ damage. More than 80 distinct autoimmune diseases have been identified, ranging from organ-specific conditions like type 1 diabetes and Hashimoto’s thyroiditis to systemic diseases like lupus that can affect multiple organs simultaneously. The reasons a person’s immune defenses turn inward involve a tangle of genetics, hormones, infections, and environmental exposures, and the science behind these conditions has shifted dramatically in just the past few decades.
How the Immune System Turns on Itself
Your immune system maintains what immunologists call tolerance: a set of checkpoints that teach immune cells to recognize the body’s own proteins as “self” and leave them alone. These checkpoints operate in two stages. First, during development, immune cells that react too strongly to the body’s own tissues are eliminated or silenced. Second, in the bloodstream and tissues, additional safeguards keep any remaining self-reactive cells in check. When either layer of this system breaks down, autoimmune disease can follow.1PubMed Central. Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells
In people with autoimmune diseases, researchers have found that the early checkpoints responsible for weeding out self-reactive B cells are often defective. The result is that large numbers of these rogue B cells accumulate in the blood, where they can present the body’s own proteins to other immune cells and escalate the attack.2PubMed Central. Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies Understanding this defect is part of what makes newer B cell-targeted therapies so promising, a topic covered later in this article.
Molecular Mimicry and Other Triggers
One of the best-studied mechanisms for kicking off autoimmunity is called molecular mimicry. The idea is straightforward: a virus, bacterium, or chemical enters the body carrying proteins that look structurally similar to the body’s own proteins. The immune system mounts a response against the invader but then, because the shapes are so close, cross-reacts with the body’s own tissues.3PubMed Central. Molecular mimicry as a mechanism of autoimmune disease This cross-reaction can trigger cytotoxic immune cells or antibodies that damage specific organs or tissues.4PubMed Central. Molecular mimicry and immune-mediated diseases Not everyone exposed to the same pathogen develops autoimmunity, though. The process requires a susceptible individual, which is why genetics and other risk factors matter so much.5PubMed. Molecular mimicry and autoimmunity
Once the initial immune attack begins, a second process can make things worse. Known as epitope spreading, it happens when the inflammation and tissue damage from the initial attack release additional self-proteins into the environment, and the immune system develops new responses against those newly exposed targets. Essentially, the damage itself creates new fronts in the war against the body’s own tissues, helping explain why many autoimmune diseases are progressive and difficult to shut down once established.6PubMed Central. Epitope spreading
A related mechanism has been documented in type 1 diabetes specifically. When the insulin-producing beta cells of the pancreas are under stress, chemical modifications to their proteins create new shapes that the immune system has never learned to tolerate. These modified proteins act as fresh targets, fueling the autoimmune response and contributing to disease progression rather than being the initial spark.7PubMed Central. Citrullination and Deamidation in Type 1 Diabetes: Linking Beta Cell Stress to Neoantigen-Driven Autoimmunity
The Genetic Landscape
Autoimmune disorders run in families, but the inheritance pattern is far messier than a single gene being passed down. The strongest genetic risk factors sit in a region of the genome known as the HLA complex, which codes for the proteins your immune cells use to present fragments of proteins (both foreign and self) for inspection. Specific variants in this region have been linked to rheumatoid arthritis, type 1 diabetes, Graves’ disease, and multiple sclerosis, among others.8PubMed Central. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action The HLA region is extraordinarily diverse across the human population, and both the protein-coding genes and the surrounding regulatory regions contribute to risk, often traveling together in inherited blocks.9PubMed. Exploring the HLA complex in autoimmunity: From the risk haplotypes to the modulation of expression
Beyond HLA, genome-wide studies have identified hundreds of smaller-effect genetic variants that each nudge risk up or down slightly. Researchers have begun combining these into polygenic risk scores that estimate a person’s overall genetic susceptibility to specific autoimmune conditions. In one study of cancer patients who responded exceptionally well to immunotherapy, those patients had significantly higher genetic risk scores for hypothyroidism, type 1 diabetes, and psoriasis compared to typical cancer patients.10npj precision oncology. Polygenic risk scores for autoimmune related diseases are significantly different in cancer exceptional responders That finding hints at a broader theme: the same immune-system aggressiveness that predisposes someone to autoimmunity may also make their immune system better at attacking cancer, a trade-off discussed further below.
Why Women Are Hit Harder
The majority of autoimmune diseases affect more women than men. Lupus, for instance, is roughly nine times more common in women, and Sjögren’s syndrome and systemic sclerosis show similarly lopsided ratios. For a long time the leading explanation was sex hormones, and hormones clearly play a role. Estrogen tends to boost certain arms of the immune response, while testosterone has broadly immunosuppressive effects.11PubMed. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity The fact that many autoimmune diseases flare during reproductive years and that onset patterns sometimes shift around puberty supports the hormonal explanation.12PubMed Central. Sex hormone influence on female-biased autoimmune diseases hints at puberty as an important factor in pathogenesis
But newer research points to a factor that may be even more important: the X chromosome itself. Women carry two X chromosomes, and in every female cell one of them is supposed to be silenced through a process called X chromosome inactivation. Some genes escape that silencing, however, meaning women can end up with a double dose of certain immune-related gene products. Studies in both humans and mice now suggest that the number of X chromosomes, rather than sex hormones alone, is associated with higher autoimmune risk, particularly for rheumatic diseases like lupus and Sjögren’s syndrome.13PubMed Central. The Inactive X Chromosome: A Genetic Driver of Female-Biased Rheumatic Autoimmune Disorders? The genes that escape X-inactivation provide a plausible biological basis for that extra immune activation women experience.14PubMed Central. Escape from X chromosome inactivation and female bias of autoimmune diseases
Infections, Sunlight, and Toxic Exposures
Among environmental triggers, infections get the most attention. The strongest case has been made for Epstein-Barr virus and multiple sclerosis. A landmark study published in Science found that EBV infection is essentially a prerequisite for developing MS: almost everyone who develops MS was previously infected with the virus, and the risk of MS increases dramatically after EBV infection.15PubMed. Epstein-Barr virus and multiple sclerosis Epidemiological data consistently support the idea that EBV is a necessary, though not sufficient, risk factor for MS, meaning the virus alone does not guarantee the disease but appears to be required for it to develop.16PubMed Central. Epstein-Barr Virus in Multiple Sclerosis: Past, Present, and Future Since most adults worldwide carry EBV, other factors clearly determine who among the infected goes on to develop MS.
Sunlight exposure, or the lack of it, is another piece of the puzzle. Several autoimmune diseases, including MS, type 1 diabetes, and rheumatoid arthritis, are more common at higher latitudes where people get less UV exposure. UV radiation appears to suppress certain immune responses through multiple pathways, and low vitamin D levels (which correlate with low sun exposure) have been linked to disease onset for all three conditions, though the evidence for vitamin D supplementation as a preventive measure is not definitive.17PubMed Central. Exposure to UV Wavelengths in Sunlight Suppresses Immunity. To What Extent is UV-induced Vitamin D3 the Mediator Responsible? For MS specifically, one prospective study found that higher vitamin D levels were associated with lower MS risk in white individuals, but not in Black or Hispanic individuals, suggesting the relationship is more complex than simply taking a supplement.18PubMed Central. Does Vitamin D Affect Risk of Developing Autoimmune Disease?: A Systematic Review
Chemical and industrial exposures have also emerged as contributors. The worldwide incidence of autoimmune disease has been rising faster than genetics alone could explain, and epidemiological research has identified toxic metals like mercury, lead, and cadmium, as well as endocrine-disrupting chemicals like bisphenol A and phthalates, as factors that can disrupt immune balance. These substances accumulate in tissues and promote autoimmunity through oxidative stress, molecular mimicry, and epigenetic changes that alter how immune-related genes are expressed.19PubMed. Environmental toxins and toxic metals in autoimmune diseases: Sex differences, hormonal influences, and immune dysregulation The growing body of epidemiological evidence linking chemical pollutants, drugs, and heavy metals to autoimmune disease has prompted researchers to view environmental toxins as a key factor in the rapid increase of these conditions globally.20PubMed Central. Exposure to Environmental Toxins and Autoimmune Conditions
The Gut Connection
The intestinal lining serves as a barrier between the massive microbial ecosystem in the gut and the immune system just beneath it. When that barrier becomes more permeable, a condition sometimes called “leaky gut,” bacterial products and food antigens can cross into the underlying tissue and provoke immune responses. A growing body of evidence from animal models and clinical studies suggests that this increased intestinal permeability may play a role in triggering or worsening autoimmune conditions. One emerging idea is that if the barrier function can be restored, the chain of events leading from genetic susceptibility to full-blown autoimmunity might be interrupted.21PubMed Central. Leaky Gut and Autoimmunity: An Intricate Balance in Individuals Health and the Diseased State This is still an active area of research, not yet translated into reliable clinical interventions, but it has shifted how researchers think about the environmental side of autoimmune disease.
Diagnosis Is Rarely Straightforward
One of the most frustrating aspects of autoimmune disease for patients is how long diagnosis can take. Many autoimmune conditions share overlapping symptoms like fatigue, joint pain, and brain fog, and there is no single blood test that confirms “autoimmune disease” as a category. One common screening tool is the antinuclear antibody (ANA) test, which checks for antibodies that target components of cell nuclei. The problem is that about 20% of the general population tests positive for ANA, yet very few of those people will ever develop an autoimmune disease. In a large cohort study of over 70,000 individuals, a positive ANA was strongly associated with lupus and other autoimmune conditions in people who had them, but in people without autoimmune disease, a positive ANA was linked to only a handful of conditions like Raynaud’s syndrome.22PubMed Central. Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease
Because of these limitations, clinicians increasingly use a layered approach: ANA screening as a first pass, followed by more specific antibody profiling to identify the exact autoimmune targets involved. When researchers compared this dual-method approach, they found that antigen-specific autoantibodies were identified in only about a third of ANA-positive samples, underscoring how many positive ANA results do not point to a specific autoimmune diagnosis.23PubMed. Comparative evaluation of antinuclear antibody detection by indirect immunofluorescence and line immunoassay with clinical correlation in suspected autoimmune disease patients: a retrospective cross-sectional study A positive ANA, in other words, is a reason for further investigation, not a diagnosis in itself.
Treatment Today and on the Horizon
For most autoimmune diseases, the treatment goal is to suppress the overactive immune response without leaving the patient dangerously vulnerable to infections. Traditional approaches use broad immunosuppressive drugs that dial down the immune system as a whole. Biologic therapies, which target specific molecules involved in the immune cascade, offer a more precise alternative. These drugs have transformed outcomes in conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis, though they come with drawbacks including high cost, the inconvenience of intravenous administration, and side effects that limit their use as first-line options for many patients.24PubMed Central. Biologic therapy for autoimmune diseases: an update
The most exciting development in recent years has been the experimental use of CAR T-cell therapy, a technique originally developed for blood cancers, to treat severe autoimmune disease. In this approach, a patient’s own T cells are collected, engineered to target and destroy B cells (which are producing the harmful autoantibodies), and then infused back. In an early case series of 15 patients with severe lupus, inflammatory myositis, or systemic sclerosis, every patient achieved remission after a single infusion, and all were able to stop their immunosuppressive medications entirely.25PubMed. CD19 CAR T-Cell Therapy in Autoimmune Disease – A Case Series with Follow-up An earlier report of five patients with severe lupus showed similarly dramatic results: all five achieved drug-free remission within three months. When B cells eventually reappeared in these patients, the new B cells were immature and carried non-class-switched receptors, as if the immune system had been “reset.”26Nature Medicine. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Another frontier involves regulatory T cells, a specialized population of immune cells whose job is to keep the rest of the immune system in check. In early-phase trials for type 1 diabetes, infusions of a patient’s own regulatory T cells were well tolerated, and in one trial involving recently diagnosed children, roughly two-thirds achieved clinical remission at 12 months.27PubMed Central. Regulatory T-cell therapy approaches These are small, early studies, and the approach remains years from routine clinical use, but the concept of retraining or rebalancing the immune system rather than simply suppressing it represents a genuinely different direction.
When Cancer Treatment Triggers Autoimmunity
There is an ironic flip side to autoimmune disease. Cancer immunotherapy drugs called immune checkpoint inhibitors work by releasing the brakes on the immune system so it can attack tumors more aggressively. Those same brakes, however, are what normally prevent autoimmune responses. Blocking them can lead to a broad range of autoimmune-like side effects, including skin rashes, colitis, hepatitis, lung inflammation, and thyroid disorders.28BMJ. Autoimmune complications of immunotherapy: pathophysiology and management These immune-related adverse events can occur quickly and sometimes affect multiple organ systems in the same patient, requiring careful monitoring throughout treatment.29PubMed. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab
This overlap between anti-cancer immunity and autoimmunity is more than a clinical headache. It reflects the fundamental tension at the heart of how the immune system is designed. A more vigilant immune system may catch more cancer cells, but it also carries a higher risk of attacking healthy tissue. Researchers have described this as an inherent trade-off: the same aggressive immunosurveillance that evolved to protect against pathogens and tumors inevitably creates vulnerability to self-attack.30PubMed Central. Robustness trade-offs and host-microbial symbiosis in the immune system
Organ-Specific Versus Systemic Disease
Autoimmune disorders are broadly grouped into those that target a single organ and those that affect the body more widely. Hashimoto’s thyroiditis and type 1 diabetes are organ-specific: the immune attack is concentrated on the thyroid gland and the pancreatic beta cells, respectively. Lupus, rheumatoid arthritis, and systemic sclerosis are systemic, meaning they can involve the skin, joints, kidneys, lungs, and other organs in varying combinations.31PubMed Central. Immunogenetic mechanisms for the coexistence of organ-specific and systemic autoimmune diseases The distinction matters clinically because organ-specific diseases tend to have more predictable courses, while systemic diseases can be harder to manage and require broader immunosuppression.
It is also common for one person to develop more than one autoimmune condition. Someone with type 1 diabetes, for example, has a higher-than-average chance of developing thyroid disease or celiac disease. This clustering is partly explained by shared genetic susceptibility in the HLA region and partly by the fact that once tolerance breaks down in one area, the same mechanisms (epitope spreading, checkpoint defects) can spill over to other tissues.
When Autoimmunity Starts in Childhood
Most autoimmune diseases can begin at any age, but the picture often looks different in children. Childhood-onset lupus, for example, tends to present more aggressively than the adult form, with more severe kidney involvement and a disease course that is two to three times more likely to be fatal.32PubMed Central. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus Juvenile idiopathic arthritis, the most common autoimmune joint disease in children, can affect growth and development in ways that adult-onset rheumatoid arthritis does not. Children also face the additional burden of managing a chronic immune condition during years critical for education, social development, and physical growth, making early diagnosis and multidisciplinary care especially important.
The Evolutionary Trade-Off
From an evolutionary perspective, autoimmune disease is not simply a malfunction. The immune variants that raise autoimmune risk often exist in the population because they provided survival advantages against infections. A well-studied example involves HLA-B27, a genetic variant strongly associated with ankylosing spondylitis (an autoimmune form of spinal arthritis) that appears to offer better defense against certain viral infections. Other examples include signaling pathways involved in the IL-23 immune response and antibodies against modified proteins, all of which help fight pathogens but increase the risk of self-attack as a side effect.33PubMed. The evolutionary trade-off between immunosurveillance and self-tolerance: Insights from four rheumatologic themes In other words, autoimmune disease is partly the price our species pays for having an immune system powerful enough to survive a world full of microbes. The same architecture that makes immune defense robust also makes it fragile in specific, predictable ways.34PubMed Central. Robustness trade-offs and host-microbial symbiosis in the immune system
This framing helps explain a puzzle that frustrated scientists for half a century. When Paul Ehrlich coined the phrase “horror autotoxicus” around 1900, he was expressing the widespread assumption that the body’s immune system simply could not turn on itself, that nature had built in an absolute prohibition against self-harm.35PubMed. Autoimmune disease: Conceptual history and contributions of ocular immunology It took until the 1950s, with seminal studies of chronic thyroiditis and the discovery of autoantibodies, for the medical establishment to accept that autoimmune disease was real.36Rheumatology & Autoimmunity. Origins and history of autoimmunity—A brief review The modern understanding has moved well past Ehrlich’s framing. Self-attack is not a catastrophic failure of an otherwise perfect system. It is a predictable, if unfortunate, consequence of the compromises that make robust immunity possible in the first place.